Summary
BeiGene, Ltd. (ONC) filed an 8-K on September 21, 2020, to report significant clinical trial data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The key updates focus on two promising drug candidates: tislelizumab and pamiparib. Investors should note the initial data from the Phase 3 RATIONALE 304 trial of tislelizumab, an anti-PD-1 antibody, when used in combination with chemotherapy for first-line treatment of non-squamous non-small cell lung cancer (NSCLC).
Key Highlights
- 1Presented initial data from the Phase 3 RATIONALE 304 trial for tislelizumab in combination with chemotherapy for first-line treatment of advanced/metastatic non-squamous NSCLC.
- 2Reported first data from a pivotal Phase 2 trial for pamiparib, an investigational PARP inhibitor, in advanced ovarian cancer (OC).
- 3Clinical data was presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
- 4Tislelizumab is an anti-PD-1 antibody.
- 5Pamiparib is an investigational PARP inhibitor.
- 6The reported data relates to the potential efficacy of these treatments in significant cancer indications.